Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 versus HEPARIN UFH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 versus HEPARIN UFH.
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% vs Heparin (UFH)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin sodium binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa), thereby inhibiting coagulation.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
Initial IV bolus of 5000 units, followed by continuous IV infusion at 1300 units/hour (typically 25,000 units in 500 mL D5W at 26 mL/hour) for therapeutic anticoagulation; dose titrated to aPTT 1.5-2.5 times control.
Intravenous: Initial bolus of 80 units/kg (or 5000 units) followed by continuous infusion of 18 units/kg/h (or 1300 units/h), adjusted to maintain aPTT 1.5-2.5 times control. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (range 1–2 hours) after intravenous administration; dose-dependent: at therapeutic doses, half-life is about 1 hour; at higher doses, up to 2.5 hours. Clinical context: shorter half-life in pulmonary embolism, longer in renal impairment.
0.5–2 hours (dose-dependent; at therapeutic doses, ~1–2 h; with higher doses, up to 2.5 h). Clinical context: shorter half-life in pulmonary embolism; prolonged in hepatic or renal impairment.
Renal: negligible; primarily metabolized by the liver and reticuloendothelial system; small amount excreted unchanged in urine (<5%). Biliary/fecal: minimal.
Primarily cleared via reticuloendothelial system and metabolism; renal excretion of unchanged drug is minimal (<5%).
Category A/B
Category A/B
Anticoagulant
Anticoagulant